Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Abstract Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-der...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Brian G. Rash, Kevin Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain‐Moss, Zarin Zainul, Brittany Varnado, Kevin Peterson, Michael Brown, Thiago Peixoto Leal, Steven Kopcho, Raul Carballosa, Paayal Patel, Mark Brody, Brad Herskowitz, Ana Fuquay, Savannah Rodriguez, Alan F. Jacobson, Ramón Fernández de León, Michael A. Pfeffer, Julie Schwartzbard, Jeffrey Botbyl, Anthony A. Oliva, Joshua M. Hare
Formáid: Artigo
Teanga:Béarla
Foilsithe / Cruthaithe: 2025
Rochtain ar líne:https://doi.org/10.1038/s41591-025-03559-0
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Ar líne

https://doi.org/10.1038/s41591-025-03559-0

Míreanna comhchosúla